• Explore /
  • Poster
  • / Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.

Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.

Abstract Poster

Authors

null

Aurore Perrot

Department of Hematology, University Hospital, Vandoeuvre-Lès-Nancy, France

Aurore Perrot , Thierry Facon , Torben Plesner , Saad Zafar Usmani , Shaji Kumar , Nizar J. Bahlis , Karthik Ramasamy , Murielle Roussel , Carla Araujo , Arnaud Jaccard , Michel Delforge , Caroline McKay , Katharine Gries , Jeremiah Trudeau , Cyrille Hulin , Katja Weisel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT02252172

Citation

J Clin Oncol 37, 2019 (suppl; abstr 8016)

DOI

10.1200/JCO.2019.37.15_suppl.8016

Abstract #

8016

Poster Bd #

342

Abstract Disclosures

Similar Posters

First Author: Thierry Facon

First Author: Sebastian Grosicki

First Author: Evangelos Terpos

First Author: Saad Zafar Usmani